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Immunology has recently penetrated the field of atherothrombosis. A number of 
human and experimental studies have documented that both cellular and molecular 
immune effectors are involved at various stages of the pathological process 1. This 
has directed our attention towards the use in atherothrombosis of immunomodulatory 
strategies, commonly employed for the prevention and treatment of other chronic 
inflammatory diseases. The administration of immunosuppressive drugs is the most 
common approach for treating immune-mediated diseases. However, the long-term 
administration of non-antigen-specific agents that cannot distinguish between 
beneficial and destructive immune responses is a major drawback of this strategy. 
 
Interesting alternatives consist of strategies aimed at potentiating the physiological 
regulatory mechanisms, if defective. In the field of atherothrombosis research, 
experimental studies have clearly shown that a defect in regulatory CD4+ T cells 
(Tregs) favors atherogenesis (reviewed in ref. 2). Based on their potent 
immunosuppressive activity, the expansion of the Treg compartment by cell transfer 
or stimulating molecules can be envisaged as a new therapeutic strategy. 
 
These findings have provided a strong incentive to perform clinical studies with the 
aim of assessing whether a defective Treg compartment is associated with the 
progression of atherosclerotic disease and the occurrence of atherothrombotic 
manifestations in humans. Three previous clinical studies, in a limited number of 
patients with coronary artery disease, first reported that patients with acute coronary 
syndromes have lower numbers of and/or inefficient Tregs in their blood 3-5. A larger 
clinical study reported in this issue 6 interestingly challenges these findings and a 
second study 7 explores the role of Tregs in stenotic and dilative pathological 
remodeling of atherosclerotic aortas. 
 
Prior to opening the debate on the role of Tregs in clinical atherothrombosis, it is 
important to reach a consensus on the phenotypic markers of Tregs. Indeed, the 
definition of these suppressive T cells can be equivocal due to their heterogeneous 
origin and to consistent differences in their characteristic markers between humans 
and mice. Initially, Tregs were defined as CD4+CD25+/high. Because this population 
may also include activated effector T cells, it is not surprising that the number of 
Tregs reported is highly variable and does not differ between healthy individuals and 
patients suffering from coronary artery disease 5, 6 or abdominal aortic aneurysm 8. 
The demonstration that Tregs require the forkhead box P3 transcription repressor 9, 10 
has allowed discrimination of Tregs among CD4+CD25+ T cells. However, this 
requires a complex (intracellular) staining technique which is suitable for 
experimental studies but difficult to use routinely in longitudinal clinical studies. To 
overcome this technical hurdle, one can use the (low) CD127 expression as a 
surrogate marker of Tregs 11. 
 
By using this identification strategy, Ammirati et al.6 have identified circulating Tregs 
as CD3+CD4+CD25highCD127low in patients with carotid or coronary atherosclerosis 
and have evaluated the diagnostic/pronostic value of measuring their circulating 
levels. While the previous studies reported a significant decrease in the percentage 
of blood Treg levels in patients suffering from myocardial infarction 3-5, Ammirati et 
al. 5 found that these levels were, on the contrary, significantly increased (Table) in 
the blood of these patients. 
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Even though the methodology employed to identify Tregs was different, the patient 
population and the time of sampling was similar in the four studies and therefore one 
cannot advocate methodological issues to explain the different results. This means 
that the evidence for a role for Tregs in myocardial infarction requires further 
clarification. To this aim, it is mandatory to firstly establish the biological significance 
of circulating Tregs. Indeed, a variation in the number of Tregs in the blood may 
either reflect a global change of the pool or that, at the time of sampling, they have 
been redistributed between the blood and the sites of inflammation. Recent 
experimental work suggests that Tregs in the vascular compartment infiltrate the 
inflamed tissue, migrate to draining lymphoid organs where they suppress the 
generation of immune effectors, and then recirculate back to the inflamed tissue, 
where they contribute to the downregulation of local immune responses 12. Therefore, 
the dynamics of Treg trafficking hampers the interpretation of their peripheral blood 
count at a given time-point. 
 
In unstable angina, however, the four clinical studies consistently found that the 
percentage of circulating Tregs is decreased, suggesting that this characterizes 
patients with acute coronary syndromes without evidence of myocardial necrosis. 
How can we interpret this finding? Like the authors, we could hypothesize that these 
patients suffer from a global Treg defect, possibly favoring the destabilization of 
coronary atherosclerosis. However, we can also envisage that Tregs of these 
patients are reduced in the bloodstream because they have been massively recruited 
at the sites of unstable coronary arteries where they might attempt to control the 
inflammatory reaction. If we extrapolate this concept to the whole acute coronary 
syndrome cohort, this could explain the difference with patients suffering from 
myocardial infarction. The relative increase in Tregs in the blood of the latter, 
reported by Ammirati et al. 6, may indeed reflect an insufficient recruitment of these 
cells in the inflamed arterial and/or myocardial tissue. Consequently, unrestrained 
local inflammation would precipitate the transition from unstable angina towards 
myocardial infarction. If this hypothesis is correct, Treg-based therapeutic strategies 
will have to overcome the mechanisms that prevent Treg from entering the target 
tissue in these patients. 
 
The two articles published in this issue also point to another interesting aspect: The 
role of Treg in chronic manifestations of atherosclerosis may depend upon the type of 
vascular remodeling. Indeed, both studies show that in the case of inward 
remodeling, leading to stenosis of either coronary 6 or carotid 6 arteries or the aorta 7, 
the blood Treg count is normal. The clinical value of peripheral Tregs in patients with 
stable, occlusive atherosclerotic disease thus appears rather limited, both in 
diagnosis and as a prognostic marker. Indeed, the blood Treg level was not able to 
predict either the presence or the progression of carotid atherosclerosis in the six-
year follow-up study of Ammirati et al.6. In a pathophysiological perspective, the fact 
that peripheral Tregs are normal in these patients can be interpreted in at least two 
ways: either human atherogenesis does not involve a Treg defect or the Treg 
compartment is efficient in maintaining tolerance and preventing the inflammatory 
events that precipitate the occurrence of atherothrombotic events. 
 
In contrast, in patients with dilative vascular remodeling of atherosclerotic aortas 
(AAA), Yin et al. 7 found that blood Treg levels are reduced and display a defective 
suppressive function in vitro. Taken together, the results of these two studies suggest 
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that Tregs may be particularly important for the control of the immune effectors that 
are involved in arterial wall dilation and thrombosis, two pathological features 
common to AAA and acute coronary syndromes. 
 
Future experimental and clinical studies are warranted to establish the clinical value 
of quantifying Tregs in atherothrombosis. Interventional experimental studies should 
aim at elucidating the causes underlying the Treg defects in atherosclerotic diseases. 
In addition, large prognostic clinical studies should serve to evaluate the Treg 
threshold that can identify patients at risk of developing life-threatening 
atherothrombotic diseases. 
 
As for the therapeutic perspective, despite the data generated in preclinical animal 
models that successfully show that Tregs can prevent or cure several T cell-mediated 
diseases, many questions remain to be addressed for the translation of this approach 
to the clinic. A major obstacle is technical and relates to cell manipulation. The 
phenotype used by Ammirati et al. 6 (CD4+CD25+CD127low) allows for the isolation 
and purification of viable autologous Tregs from the blood, but because of their 
limited number, they need to be further expanded in vitro. However, Tregs are poorly 
proliferating cells, and the ex vivo expansion of Tregs remains an unresolved issue, 
especially, when antigen-specific Tregs are desired. In fact, current expansion 
protocols generate polyspecific Tregs that may cause “pan-immunosuppression” if 
transferred in vivo. At present, the only clinical trials of immunotherapy based on 
Tregs are performed in bone marrow transplantation for the prevention or cure of 
graft-versus host disease (reviewed in ref. 13). 
 
Finally, although it appears certain that Tregs critically control atherosclerotic 
diseases, the translation of this knowledge into clinical practice will require extensive 
future work. 
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Table: Treg count variations in the blood of patients with CAD (NCA: Normal 
coronary arteries; CSA: Chronic stable angina; UA: Unstable angina; MI: Myocardial 
infarction; nd: not determined). 
 
Study  NCA  CSA  UA  MI 
  n  n Variation  n Variation  n Variation 
Mor et al. 5  28  28 =  nd nd  32   
Han et al. 4  12  18    16     24     
Cheng et al. 3  20  22    17     26     
Ammirati et 
al. 6 
 75  36 =  39    50  
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